Showing results (1851-1860 of 1,877) with videos related to

Sort By:
Pageof 188
F1000Research|April 9, 2021
Local adaptation in populations of <i>Mycobacterium tuberculosis</i> endemic to the Indian Ocean RimFabrizio Menardo, Liliana K Rutaihwa, Michaela Zwyer, et al.
Nature Communications|January 28, 2021
Integrating deep learning CT-scan model, biological and clinical variables to predict severity of COVID-19 patientsNathalie Lassau, Samy Ammari, Emilie Chouzenoux, et al.
Nature Communications|September 20, 2023
Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistanceCirino Botta, Cristina Perez, Marta Larrayoz, et al.
Science (New York, N.Y.)|April 22, 2006
Global mineralogical and aqueous mars history derived from OMEGA/Mars Express dataJean-Pierre Bibring, Yves Langevin, John F Mustard, et al.
Neuro-Oncology|April 29, 2017
Natural course and prognosis of anaplastic gangliogliomas: a multicenter retrospective study of 43 cases from the French Brain Tumor DatabaseLouis-Marie Terrier, Luc Bauchet, Valérie Rigau, et al.
Blood|January 22, 2025
Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone Induction in Newly Diagnosed Myeloma: Analysis of the MIDAS TrialAurore Perrot, Cyrille Touzeau, Jerome Lambert, et al.
Blood Cancer Journal|April 15, 2021
Genetically determined telomere length and multiple myeloma risk and outcomeMatteo Giaccherini, Angelica Macauda, Enrico Orciuolo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2025
International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple MyelomaHervé Avet-Loiseau, Faith E Davies, Mehmet K Samur, et al.
Haematologica|April 20, 2023
Real-world study of the efficacy and safety of belantamab mafodotin (GSK2857916) in relapsed or refractory multiple myeloma based on data from the nominative ATU in France: the IFM 2020-04 studyAlexis Talbot, Arthur Bobin, Léa Tabone, et al.
The Lancet. Oncology|June 18, 2024
Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trialPhilippe Moreau, Cyrille Hulin, Aurore Perrot, et al.
Pageof 188